Ryan Harding - Cell Therapies

About
Explore Cell Therapies

About Cell Therapies

Our Facility

View our Services

Partnerships and Collaborations

Careers at Cell Therapies

Contact us

Since 2003, Cell Therapies has manufactured cell therapies, ex vivo gene therapies, and regenerative medicine products under GMP standards to meet global regulatory requirements.

Learn about Cell Therapies
Services
Explore Services

Contract Manufacturing

Technology Transfer

Process Development

Analytical Testing and Development

Quality as a Service

Consulting and Advisory

Clinical Trial Support

Cryopreservation & Logistics

Digitalization & Automation

With over two decades of experience in GMP manufacturing of cell-based products, Cell Therapies is a trusted partner in transforming promising research into scalable, compliant, and commercially viable therapies.

Learn about Our Services
Facility
Careers
Explore Careers

Careers at Cell Therapies

View Current Opportunities

Upload your Resume

We are always on the lookout for curious minds, problem-solvers, and biotech enthusiasts to join our team. If you have a background in GMP manufacturing, QC, QA, engineering, or cell and gene therapy development, we would love to hear from you.

Find out about a career at Cell Therapies
News and Resources
Explore News and Resources

All News and Resources

News

Resources

Filter
All News
Resources

First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial
First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial
Read More

Arovella IND Acceptance for iNKT Cell Therapy Platform
Arovella IND Acceptance for iNKT Cell Therapy Platform
Read More

ACTRIS Signs MoU with Cell Therapies Pty Ltd to Advance CDMO Capabilities for Cell and Gene Therapies
ACTRIS Signs MoU with Cell Therapies Pty Ltd to Advance CDMO Capabilities for Cell and Gene Therapies
Read More

Read the latest from Cell Therapies
Contact

News

First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial

Melbourne, Australia The first clinical dose of PMCC-COE19, developed by Peter Mac and manufactured by…

Ryan HardingFebruary 20, 2026

News

Arovella IND Acceptance for iNKT Cell Therapy Platform

Melbourne, Australia Our client Arovella Therapeutics Ltd (ASX: ALA) recently announced that the U.S. Food…

Ryan HardingFebruary 18, 2026

News

ACTRIS Signs MoU with Cell Therapies Pty Ltd to Advance CDMO Capabilities for Cell and Gene Therapies

Cell Therapies CEO Bev Menner and ACTRIS Executive Director, A/Prof Aloysius Ho, at Cell Therapies'…

Ryan HardingFebruary 11, 2026

News

Cell Therapies and ENCell Forge Strategic APAC Partnership to Advance Cell and Gene Therapy Manufacturing

Cell Therapies CEO Bev Menner and ENCell Director, CDMO Business Development Gonson Yeom at Cell…

Ryan HardingDecember 5, 2025